Albiglutide - GlaxoSmithKline

Drug Profile

Albiglutide - GlaxoSmithKline

Alternative Names: Albugon; Albumin-GLP-1 fusion protein; Albumin-glucagon-like peptide-1 fusion protein; Eperzan; GLP-1-albumin fusion protein; Glucagon-like peptide-1-albumin fusion protein; GSK 716155; Syncria®; Tanzeum

Latest Information Update: 04 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Human Genome Sciences
  • Developer GlaxoSmithKline
  • Class Albumins; Antihyperglycaemics; Glucagon-like peptides; Obesity therapies; Recombinant fusion proteins
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Phase II Type 1 diabetes mellitus
  • Discontinued Heart failure

Most Recent Events

  • 18 Oct 2017 GlaxoSmithKline completes a phase II trial in Type-1 diabetes mellitus (Adjunctive treatment, Newly diagnosed) in France, Germany, Italy, Spain and United Kingdom (SC) (NCT02284009)
  • 14 Sep 2017 GlaxoSmithKline withdraws a phase III trial for Type-2 diabetes mellitus (In children, In adolescents) as the asset will be withdrawn from the market prior to study end in USA (SC) (NCT03015519)
  • 24 Jul 2017 GlaxoSmithKline completes a phase III trial for Type-2 diabetes mellitus in Denmark, Hungary, USA, Brazil, Canada, France, Germany, Italy, South Korea, Mexico, Philippines, Poland, South Africa, United Kingdom and Spain (NCT02229227)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top